The device, called the Argus II and developed by Los Angeles-based medical device company Second Sight Medical Products, is already available in Europe. It implants electrodes in the retina of visually-impaired persons suffering from retinitis pigmentosa or macular degeneration, and uses video-capturing glasses to send images to the brain.
Second Sight has spent $200 million developing the product, half of which came from investors and the rest through federal grants.
More Articles on Medical Devices:
Zimmer’s 4Q Profits Drop 2.4% to $153M
Medical Device Tax Gathers $97M From Revenue in January
Sightpath Medical to Mobilize Femtosecond Laser for Cataract Surgery
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
